Every 424B that Enveric Biosciences, Inc. (ENVB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ENVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENVB filings page.
Enveric Biosciences files a prospectus supplement updating an at-the-market (ATM) facility to offer up to $2,425,000 aggregate offering price of Common Stock pursuant to an ATM Agreement with H.C. Wainwright & Co., LLC.
The supplement states Enveric has previously sold $3,199,400.98 of Common Stock under the ATM Agreement and sold $4,483,711.04 of securities under General Instruction I.B.6 of Form S-3 in the prior 12 months. The one-third limitation under General Instruction I.B.6 applies based on non-affiliate market value, and the supplement ties the updated offering limit to that rule.
Enveric Biosciences is registering for resale up to 6,822,225 shares of its common stock. The registration covers (i) 98,000 issued shares and (ii) up to 6,724,225 shares issuable upon exercise of various warrants and pre-funded warrants from a April 16, 2026 private placement, including Placement Agent Warrants.
The filing states the company will not receive any proceeds from resales and that the registration satisfies registration rights granted in the Private Placement. The prospectus notes a reported Nasdaq closing price of $3.37 per share on April 21, 2026 and includes per-holder examples and Beneficial Ownership Limitations of 4.99% and 9.99%.
Enveric Biosciences filed a prospectus registering 680,620 shares of Common Stock. The registration covers up to 328,802 shares issuable upon exercise of Series G Warrants, up to 328,802 shares issuable upon exercise of Series H Warrants, and 23,016 shares issuable upon exercise of Placement Agent Warrants.
The prospectus states the Company will not receive proceeds from sales by the Selling Stockholders, but will receive net proceeds if the January 2026 Warrants are exercised for cash. The exercise prices are $4.16 for the Series G and H Warrants and $5.5125 for the Placement Agent Warrants. The document cites 1,390,335 shares outstanding as of February 4, 2026 and an assumed post‑exercise outstanding share count of 2,070,955 if all January 2026 Warrants are exercised. The prospectus notes a last reported Nasdaq sale price of $2.84 on February 4, 2026.
Enveric Biosciences, Inc. is launching an at-the-market stock offering of up to $1,346,000 of common stock under its existing $200 million shelf registration. The company has entered into an agreement with H.C. Wainwright & Co., which will act as sales agent.
Shares may be sold from time to time on Nasdaq or other markets at prevailing prices, with Wainwright earning a 3.0% fee on gross proceeds. If shares were sold at $2.84, the recent Nasdaq price, common stock outstanding could increase from 1,390,335 to about 1,864,278 shares.
Enveric plans to use any net proceeds primarily to develop its lead drug candidate EB-003, a non-hallucinogenic neuroplastogenic compound for difficult mental health disorders, and for general corporate purposes such as research and development, working capital, possible debt reduction, acquisitions and capital expenditures. The filing highlights risks including potential share price pressure from additional stock sales, dilution from equity and warrant overhang, and the company’s need for ongoing access to capital within Form S-3 public float limits.
Enveric Biosciences is selling 328,802 shares of common stock in a registered direct offering at $4.41 per share, for gross proceeds of $1,450,016.82. Net proceeds are estimated at about $1.25 million after placement fees and expenses.
In a concurrent private placement, investors will also receive unregistered Series G and Series H warrants to purchase up to 328,802 shares each at an exercise price of $4.16 per share. Enveric plans to use the cash primarily for product development, working capital, and general corporate purposes. After the sale, common shares outstanding are expected to be 1,390,335, excluding shares issuable from warrants and equity awards.
Enveric Biosciences Inc. has filed a prospectus covering the resale by existing investors of up to 418,313 shares of common stock issuable upon exercise of Series C, Series D and placement agent warrants. These shares are being registered for the selling stockholders, so Enveric will not receive proceeds from their resale, and will receive cash only if the warrants are exercised for cash rather than on a cashless basis. The warrants, most with an exercise price of $10.98 per share and the placement agent warrants at $13.7256, become exercisable only after stockholders approve the underlying share issuance, which Enveric is required to seek at a special meeting.
The warrant exercise inducement completed in September 2025 generated approximately $2.2 million in gross proceeds, supporting product development and working capital. Enveric recently effected a 1‑for‑12 reverse stock split and continues to post sizable net losses, reflecting its status as a clinical‑stage biotech developing non‑hallucinogenic neuroplastogenic drugs led by EB‑003 for difficult psychiatric and neurological disorders.